LOSARTAN POTASSIUM- losartan potassium tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89)

Inapatikana kutoka:

KAISER FOUNDATION HOSPITALS

INN (Jina la Kimataifa):

LOSARTAN POTASSIUM

Tungo:

LOSARTAN POTASSIUM 25 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive

Bidhaa muhtasari:

Losartan potassium tablets USP are available as follows: 25 mg - light green, oval-shaped, film-coated tablets, debossed with “93” on one side and “7364” on the other side, in bottles of 100 (NDC 0179-0200-01). 50 mg - green, oval-shaped, film-coated tablets. On one side of the tablet debossed with “7365”, on the other side of the tablet debossed with “9” on one side of the breakline and “3” on the other side of the breakline, in bottles of 100 (NDC 0179-0202-01). 100 mg - dark green, oval-shaped, film-coated tablets, debossed with “93” on one side and “7366” on the other side, in bottles of 100 (NDC 0179-0203-01). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed. Protect from light. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

LOSARTAN POTASSIUM- LOSARTAN POTASSIUM TABLET, FILM COATED
KAISER FOUNDATION HOSPITALS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LOSARTAN POTASSIUM TABLETS SAFELY
AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LOSARTAN
POTASSIUM TABLETS.
LOSARTAN POTASSIUM TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1995
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WHEN PREGNANCY IS DETECTED, DISCONTINUE LOSARTAN POTASSIUM TABLETS AS
SOON AS POSSIBLE. DRUGS THAT ACT
DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO
THE DEVELOPING FETUS. ( 5.1)
INDICATIONS AND USAGE
Losartan potassium tablets are an angiotensin II receptor blocker
(ARB) indicated for:
Treatment of hypertension, to lower blood pressure in adults and
children greater than 6 years old. Lowering blood
pressure reduces the risk of fatal and nonfatal cardiovascular events,
primarily strokes and myocardial infarctions. ( 1.1)
Reduction of the risk of stroke in patients with hypertension and left
ventricular hypertrophy. There is evidence that
this benefit does not apply to Black patients. ( 1.2)
Treatment of diabetic nephropathy with an elevated serum creatinine
and proteinuria in patients with type 2 diabetes
and a history of hypertension. ( 1.3)
DOSAGE AND ADMINISTRATION
Hype rte nsion
Usual adult dose: 50 mg once daily. ( 2.1)
Usual pediatric starting dose: 0.7 mg per kg once daily (up to 50 mg).
( 2.1)
Hypertensive Patients with Left Ventricular Hypertrophy
Usual starting dose: 50 mg once daily. ( 2.2)
Add hydrochlorothiazide 12.5 mg and/or increase losartan potassium to
100 mg followed by an increase to
hydrochlorothiazide 25 mg if further blood pressure response is
needed. ( 2.2, 14.2)
Nephropathy in Type 2 Diabetic Patients
Usual dose: 50 mg once daily. ( 2.3)
Increase dose to 100 mg once daily if further blood pressure response
is needed. ( 2.3)
DOSAGE FORMS AND STRENGTHS
Tablets: 25 mg; 50 mg; and 100 mg. ( 3)
CONTRAINDI